Fig. 4
In vivo antitumor efficacy of BGLSP. (A) Tumor specimens from control and BGLSP-treated (2 mg/kg/day) groups at day 21. (B) Tumor growth kinetics. (C) Final tumor weights. (D, E) Immunohistochemical staining and expression of Ki-67 proliferation index. Scale bar: 50 μm. (F) H&E-stained tumor histopathology. Scale bar: 50 μm. (G, H) Western blot analysis of EMT and apoptosis-related protein expression in tumor tissues. Data presented as mean ± SD (n = 6 per group). Statistical comparisons were performed by two-way ANOVA (B) and unpaired Student’s t-test (C, E, H). *P < 0.05, **P < 0.01, ***P < 0.001. Original blots are presented in Supplementary Fig. 6.
